Why the study?
Several biomarkers have been studied to better assess renal function and identify patients at risk of worsening renal function in cardiorenal syndrome, prompting a review of their clinical usefulness.
This review highlights the potential clinical utility of novel biomarkers for assessing renal function and predicting worsening renal function in patients with cardiorenal syndrome.
Does not yet support routine use in cardiorenal syndrome; leaves open prospective validation studies.
Cardiorenal syndrome is a clinical manifestation of the bidirectional interaction between the heart and kidney diseases. Over the last years, in patients with cardiovascular diseases, several biomarkers have been studied in order to better assess renal function as well as to identify patients prone to experiencing chronic or acute worsening of renal function. The aim of this review is to focus on the possible clinical usefulness of the most recent biomarkers in the setting of cardiorenal syndrome.
No takes yet. Share an insight, caveat, or question.
Goffredo et al. (2021) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: